Program - Association for Chemoreception Sciences

12:05 pm #43 Reduced Avoidance Response to Predator OdorantsAssociated with Wiring Defects in the Olfactory Systemof Robo-2 Mutant Mice.Jean-François Cloutier 1,2 , Manon Lépine 1,2 , Tyler Cutforth 3 ,Jin H. Cho 1,2 . 1 Montreal Neurological Institute, Montreal, QC,Canada, 2 McGill University, Montreal, QC, Canada,3UC Santa Cruz, Santa Cruz, CA, United States12:45 pm – 2:45 pm CLINICAL LUNCHEON (Ticketed Event)NEW CLINICAL TRIAL FUNDING OPPORTUNITIESAT NIDCDChair/Organizer: Claire MurphyGordon Hughes. Program Officer, Clinical Trials, NIDCDHorizons#44 The National Institute on Deafness and Other CommunicationDisorders is committed to building and expanding its clinicaltrials program to promote the development of interventions totreat or prevent disorders in hearing, balance, taste, smell, voice,speech and language. Three new clinical trial initiatives andfunding opportunities, issued in July, 2008, can be found athttp://www.nidcd.nih.gov/research/clinicaltrials.Individual application information can be found athttp://www.nidcd.nih.gov/funding/foa/. The Phase I/IIPreliminary Clinical Trial specifically targets studies that willprovide preliminary data and optimize the design of theeventual phase III trial. The Phase III Clinical Trial PlanningGrant is designed to permit early peer review of a proposedphase III clinical trial and is used to develop a detailed Manualof Procedures, train clinical sites and prepare case report forms.The Phase III Definitive Clinical Trial should have the potentialto significantly impact on clinical practice or public healthpolicy. NIDCD strongly encourages clinical trial applicationsin chemoreception sciences.S AT U R D AYProgram in Detail | 67